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Schlüsselwörter
Lungenkarzinom · Immuntherapie · Vakzine
Zusammenfassung
Das Bronchialkarzinom führt in Deutschland die Statistik
der Krebs-assoziierten Todesfälle bei Männern an, und
nimmt bei Frauen den dritten Rang ein. Mehr als 90% der
Patienten mit der Diagnose Bronchialkarzinom verster-
ben trotz der derzeit existierenden Therapien (Operation,
Radio- und Chemotherapie). Immuntherapeutische Be-
handlungsansätze könnten die Anforderungen an eine
dringend benötigte, neuartige Therapieform erfüllen: se-
lektive Wirksamkeit gegen Tumorzellen bei gleichzeitig
geringen Nebenwirkungen. Bislang litt die Entwicklung
immuntherapeutischer Behandlungsstrategien vor allem
unter dem begrenzten Wissen über relevante Tumoranti-
gene und Bronchialkarzinom-spezifische Mechanismen,
dem Immunsystem des Körpers zu entkommen. Heute
zeichnet sich allerdings ab, dass immuntherapeutische
Behandlungskonzepte ihren Platz im Rahmen multimo-
daler Behandlungsansätze im Sinne einer adjuvanten
Therapie finden werden. Bis zur klinischen Prüfung wur-
den bis heute vorwiegend unspezifische Immunmodula-
toren, die spezifische und unspezifische, zelluläre Im-
muntherapie, die therapeutische Vakzinierung und gen-
therapeutische Behandlungsstrategien in ihrer Entwick-
lung voran getrieben. Im Folgenden soll eine Übersicht
gegeben werden, die für die Therapie des Lungenkarzi-
noms relevante immuntherapeutische Behandlungsan-
sätze mit Ausnahme der Antikörper-basierten Konzepte
beleuchtet und ein besonderes Augenmerk auf neuere
Entwicklungen mit bereits abgeschlossenen klinischen
Studien legt. Trotz vielversprechender Ansätze gibt es
derzeit jedoch keine Standard-Immunotherapie für die
klinische Routine.
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Summary
In Germany lung cancer is the leading cause of cancer-
associated death in men. Surgery, chemotherapy and ra-
diation may enhance survival of patients suffering from
lung cancer but the enhancement is typically transient
and mostly absent with advanced disease; eventually
more than 90% of lung cancer patients will die of dis-
ease. New approaches to the treatment of lung cancer
are urgently needed. Immunotherapy may represent one
new approach with low toxicity and high specificity but
implementation has been a challenge because of the
poor antigenic characterization of these tumors and their
ability to escape immune responses. Several different
immunotherapeutic treatment strategies have been de-
veloped. This review examines the current state of devel-
opment and recent advances with respect to non-specific
immune stimulation, cellular immunotherapy (specific
and non-specific), therapeutic cancer vaccines and gene
therapy for lung cancer. The focus is primarily placed on
immunotherapeutic cancer treatments that are already in
clinical trial or well progressed in preclinical studies. Al-
though there seems to be a promising future for im-
munotherapy in lung cancer, presently there is not stan-
dard immunotherapy available for clinical routine.
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Introduction
Lung cancer is the leading cause for cancerous death in men in
Germany and only 12% of all patients will ever be cured of
this devastating disease. Clearly, there is still an unmet med-
ical need for new adjuvant therapies that demonstrate efficacy
in lung cancer with less associated toxicity than chemotherapy.
The unfortunate reality is, however, that the field of lung can-
cer immunotherapy, which may provide a valid alternative for
cytotoxic agents, lags behind similar efforts with other kinds of
tumors, primarily melanoma, prostate and breast cancer. The
main reasons why lung cancer remains difficult to treat by im-
munotherapeutic approaches also illustrate the difficulties of
immunotherapy to become part of the standard treatment
modalities for lung cancer:
– In contrast to other tumors such as melanoma, in lung can-
cer the relevant immunologically dominant antigens remain
unknown.
– Many tumors are able to avoid attacks by immunocompe-
tent cells by active and/or passive escape mechanisms, e.g.
by downregulating major histocompatibility complexes
(MHC) and/or antigens or by the induction of regulatory 
T cells that can suppress a destructive antitumor immune
response, and thereby become poor targets for cytotoxic 
T lymphocytes (CTL) or by creating a tumor microenviron-
ment that is very unfavorable to immunocompetent cells by
secreting immunoinhibitory factors such as transforming
growth factor-β or interleukin-10.
These general problems provide the theoretical basis for most
basic researchers and clinical investigators seeking to develop
immunotherapeutic strategies for the treatment of non-small
cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Non-specific immune stimulation can be induced by a highly
heterogenous group of molecules ranging from intact mi-
crobes and bacterial derivatives to cytokines. Most of these
agents aim at the induction of both cellular and humoral im-
mune responses by inducing a strong inflammatory response
and thus indirectly activating antigen presenting cells (APC)
such as dendritic cells. More focus has been placed on specific
and non-specific immunotherapy (active and passive) of lung
cancer. Therapeutic vaccination using autologous or allogene-
ic tumor cells (or their defined proteins or peptides) is an ex-
ample for active-specific immunotherapy that has the poten-
tial to be tumor specific as well as to have a systemic impact
with relatively few side effects. The most common gene thera-
py approaches currently applied in the treatment of lung can-
cer consist of direct genetic modification of tumor cells to re-
place defective genes (‘gene replacement’ therapy) or to insert
immune stimulating genes with the aim to induce stronger
tumor-specific immune responses (‘immunogene’ therapy).
The specific focus of this review is on immunotherapeutic
strategies for the treatment of lung cancer that have been
taken into the clinic and tested in clinical trials with emphasis
on therapeutic vaccination strategies.
Non-Specific Immune Stimulation
Agents that enhance the immune response of the host against
cancer, infectious disease, or immunologic disorders are re-
ferred to as ‘immunomodulators’. When used for the treat-
ment of cancer, immunomodulators are thought to function as
a ‘danger signal’ to the immune system by inducing changes in
APC, in particular dendritic cells, and thereby augmenting
both cellular and humoral immunity. Although multiple clini-
cal trials evaluating non-specific immune stimulation for the
treatment of lung cancer have been reported (table 1), the
success of immunomodulators in cancer immunotherapy has
been very limited. For levamisole and thymosin, negative re-
sults were reported when used as adjuvant treatment for
chemotherapy of lung cancer. While the systemic application
of cytokines such as IFN-α and GM-CSF in lung cancer pa-
tients also failed to result in significant clinical responses, GM-
CSF remains within the focus of ongoing research with the use
of gene-modified autologous tumor cell vaccines (GVAX®,
Cell Genesys, Inc., South San Francisco, CA, USA) as an ac-
tive-specific immunotherapy for NSCLC. Although the enthu-
siasm for many of the immunomodulators has decreased,
there has been a resurgence in approaches targeting co-stimu-
latory molecules such as CTLA-4, B7 family members,
CD40(L) and others. However, to our knowledge, only very
little information is available on clinical trials using this ap-
proach in patients diagnosed with lung cancer [1].
Cellular Immunotherapy (Specific and Non-Specific)
The objective of non-specific cellular immunotherapy is to en-
hance the antitumor effector mechanisms that are not depen-
dent on a specific tumor antigen. Lymphokine-activated killer
cells (LAK) are peripheral blood mononuclear cells that have
been expanded ex vivo with interleukin-2 (IL-2). In clinical
trials, LAK cell therapy was most successful in renal cell carci-
noma and melanoma, although further studies indicated that
LAK cells did not significantly improve the therapeutic effica-
cy of IL-2 alone [9]. No clinical benefit was detected after
adoptive transfer of lymph node-lymphokine-activated killer
cells (LN-LAK) combined with recombinant interleukin 2
(rIL-2) for adjuvant therapy of 19 patients with stage I
NSCLC [10]. Kimura et al. did, however, find improved sur-
vival in patients with stage II and IIIA lung cancer after treat-
ment with LAK cells and IL-2 in combination with
chemotherapy and/or radiotherapy [11, 12]. 
The use of monokine-activated killer cells (MAK) in clinical
trials for lung cancer has been described as a safe procedure
[13], however, no detailed information is available as far as
clinical outcome is concerned.
Adoptive immunotherapy (AI) by specific cellular transfer
can be divided into at least two categories: tumor-infiltrating
lymphocytes (TIL) and antigen-specific or tumor-specific cy-
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tolytic T lymphocytes (CTL). It is generally recognized that
the major effector cell responsible for antitumor immunity is
the CD8+ T cell [14]. However, aberrant MHC class I expres-
sion is a fundamental obstacle for any cell-based cancer im-
munotherapy, and NSCLC is no exception [15]. Despite these
problems, Kradin et al. [16] and Melioli et al. [17] were able to
isolate TILs from resected tumors of patients with NSCLC
and reinfused the TILs in combination with subcutaneous ap-
plication of IL-2. Further studies evaluating the therapeutic
efficacy of TIL reinfusion in patients with NSCLC have been
able to confirm the moderate clinical effectiveness found in
these trials [18]. Other approaches aimed at the isolation of
tumor-specific CTLs from the peripheral blood of lung cancer
patients that had been vaccinated with their autologous tumor
cells [19]. Cancer immunotherapy using the adoptive transfer
of TILs or CTLs has, however, seen limited application due to
poor response rates and the labor-intensive preparation of the
infusion product. Dudley et al. [20] combined the adoptive
transfer of both CD4+ and CD8+ TILs in patients with
metastatic melanoma with a non-myeloablative chemotherapy
regimen and observed impressive clinical response rates. A re-
cent update has 16 of 32 patients experiencing an objective
clinical response. Currently, clinical trials are being initiated
that transfer parts of this strategy to the treatment of other
solid tumors.
Therapeutic Vaccination
In contrast to the prophylactic vaccination against infectious
diseases, for cancer patients the only relevant vaccination
strategy must be therapeutic. Generally speaking, cancer vac-
cines incorporate a source of tumor antigens combined with
some type of ‘adjuvant’ to make these tumor antigens visible
to the immune system. Sources of tumor-associated antigens
include whole autologous or allogeneic tumor cells, defined
proteins, or specific peptide epitopes. Most likely due to the
heterogeneous histology of lung cancers, the relevant im-
munologically dominant antigens remain unknown. There-
fore, the use of autologous tumor cells might be especially
suitable for vaccination strategies in lung cancer, because no
prior knowledge of specific tumor antigens is necessary and
the induced immunity may not be confined to a single, specific
antigen that could be downregulated by the tumor. The genet-
ic modification of autologous tumor cells to secrete im-
munomodulatory cytokines has been shown to induce antitu-
mor immunity in a number of preclinical models. Of these cy-
tokines GM-CSF has demonstrated the greatest induction of
antitumor immunity [21]. Two early phase clinical trials using
GM-CSF-secreting, autologous tumor cells (GVAX) in pa-
tients with NSCLC have revealed encouraging preliminary re-
sults [22, 23]. In the second trial 83 patients (20 stage I/II, Co-
hort A; 63 stage III/IV, Cohort B) underwent tumor harvest
and vaccine cell processing. Vaccine manufacturing was suc-
cessful in 80% of patients. 90% of patients developed vaccine
site reactions. 3 advanced stage patients achieved durable,
complete tumor responses lasting 6 and 18 months, and ongo-
ing, respectively. In addition, there was one minor response
(30% decrease in a lung nodule), 2 patients with mixed tumor
responses, and 7 patients with stable disease (median duration
7.7 months). 2 of the 3 complete responders had failed prior
chemotherapy for advanced disease. Currently, further clinical
studies are underway investigating autologous GVAX vac-
cines with and without immunomodulatory doses of cy-
clophosphamide in all types of NSCLC.
The combination of immunotherapy and chemotherapy has
been shown to augment the immune response in both preclin-
ical and human trials [24]. Recent preclinical studies suggest
Phase Indication Immunomodulator Patients, n Reference
I/II NSCLC/SCLC BCG 55 [2]
I/II NSCLC/SCLC C. parvum 400 [3]
II NSCLC M. vaccae 20 [4]
I/II NSCLC/SCLC Levamisole 99 [5]
I/II SCLC Thymosin 18 [6]
I/II NSCLC IFN-α 55 [7]
I SCLC GM-CSF 13 [8]
Table 1. Clinical trials using non-specific
immunomodulators in lung cancer
Phase Stage Vaccine Patients, n Reference
II III/IV Ctx ± M. vaccae 29 [4]
I IV GVAX® 33 [22]
I/II IB–IV GVAX® 43 [23]
I IIIB/IV MUC1 17 [25]
I I/II MAGE-3 17 [27]
Table 2. Therapeutic vaccination in NSCLC –
published clinical trials
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an even higher therapeutic efficacy of cancer vaccines if the
system had been made lymphopenic and reconstituted with
autologous peripheral blood mononuclear cells (PBMC) [24].
Based on these results, a clinical pilot study in patients with
NSCLC stages IIb/IIIa is being initiated in our clinic in 2005
(Klinikum Grosshadern, Ludwig Maximilians University Mu-
nich, Germany). These patients will receive immunomodula-
tory doses of cyclophosphamide and fludarabine and a reinfu-
sion of autologous PBMCs prior to therapeutic vaccination
with irradiated autologous tumor cells in combination with the
continuous infusion of GM-CSF at the vaccination site.
Vaccination strategies in NSCLC using peptides are rare due
to the limited information that is currently available on specif-
ic tumor antigens in this disease. The carcinoma-associated
mucin, MUC1, which is expressed on the surface of many ade-
nocarcinomas but not on normal epithelial cells has been tar-
geted in a phase I trial of patients with NSCLC using the vac-
cine BLP25 [25] (table 2). A multicenter phase IIB study in-
vestigating the same vaccine in NSCLC patients with stages
IIIB and IV has recently been finished with promising results
for safety and clinical effectiveness. In this trial, patients were
stratified by treatment response and stage (IIIB locoregional
or IIIB with malignant pleural effusion/IV) and randomized
1:1 to either best supportive care (BSC) or BSC with BLP-25.
171 patients were randomized. 45% had stable disease, 51%
showed a partial response and 4% experienced a complete re-
sponse. Overall a benefit for patients receiving BSC plus vac-
cine associated with low toxicity and longer maintenance of
quality of life was observed. A phase III trial further investi-
gating BLP-25 is currently being initiated. Another peptide
vaccination strategy aims at the peptide MAGE-3, which was
originally identified as a melanoma-associated antigen and is
expressed in about 30% of lung cancers [26]. A multinational
phase II trial investigating the therapeutic efficacy of the
MAGE-3 peptide vaccine in patients with resected MAGE-3+
stage IB/II NSCLC is currently underway. First results report-
ing the successful induction of humoral and cellular immune
responses in patients with NSCLC following vaccination with
MAGE-3 with and without adjuvant have been published in
2004 [27].
Table 3 summarizes currently active vaccine trials for NSCLC
as published in the NCI’s PDQ database of cancer clinical
trials (http://www.cancer.gov/search/clinicaltrials).
In SCLC, an anti-idiotype vaccine targeting the ganglioside
GD3 (BEC2) (mitumomab) has been evaluated [28]. A pilot
study of BEC2 plus BCG was performed in 15 patients with
both limited and extensive SCLC following demonstration of
a substantial response to chemotherapy. Patients received a
series of 5 intradermal vaccinations. All patients developed
anti-BCE2 antibodies with 5 patients developing anti-GD3
antibodies. The median overall survival was 21 months with a
4-year survival rate of 40%. The European Organization for
Research and Treatment of Cancer (EORTC) is currently as-
sessing data from a phase III trial using BEC2 in combination
with induction chemoradiotherapy in limited stage SCLC.
Other therapeutic vaccination strategies for patients with
NSCLC and SCLC are in the early phase of clinical develop-
ment:
– G17DT, which links diphteria toxin to a gastrin-17 receptor
binding epitope [29] (so far, published results are limited to
treatment of gastrointestinal malignancies but SCLC reveals
high expression of gastrin),
– mp53DC, which consists of dendritic cells that had been
pulsed with mutant p53 [30],
– fucosyl GM1-KLH, another mucin peptide vaccine [31, 32],
– polysialic acid-KLH, a vaccine consisting of long chain poly-
sialic acid, which is, in adults, largely restricted to SCLC, and
keyhole limpet hemocyanin (KLH) as adjuvant [33],
– fowlpox-CEA/vaccinia-CEA, which uses viral vectors that
express the mucin CEA [34].
Phase Stage Vaccine Site
I/II n.d. allogeneic tumor cells expressing α-1,3-galactosyltransferase Bethesda, MD
Pilot unresectable III vaccinia-CEA-TRICOM, fowlpox-CEA-TRICOM, recomb. Bethesda, MD
fowlpox GM-CSF + chemotherapy/radiotherapy
II IV vaccinia-CEA-TRICOM, fowlpox-CEA-TRICOM, recomb. Washington, DC
fowlpox GM-CSF ± chemotherapy
II I–III autologous DC + allog. tumor cells Lexington, KY
I IB–IIIA autologous DC + autol. tumor cells Los Angeles, CA
II IIIB/IV BAC GVAX® Sacramento, CA 
Kansas City, KA 
New Orleans, LA 
Arlington, TX
II III autologous DC + mutant p53 peptide Bethesda, MD
II n.d. autologous tumor cells treated with interferon α or interferon 
γ + chemotherapy + GM-CSF Los Angeles, CA
n.d.: Not determined.
Table 3. Thera-
peutic vaccination in
NSCLC – currently
active clinical trials as
published in the
NCI’s PDQ‚ database
of cancer clinical
trials
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Lung Cancer Gene Therapy
Even though gene therapy is not the primary focus of this re-
view, a short overview should be given since both hereditary
and environmental factors are causative of genetic abnormali-
ties in lung cancer.
‘Gene Replacement’ Therapy
Preclinical and clinical studies in this area of gene therapy re-
search aim mostly at the most commonly mutated gene in lung
cancer: p53 (mutations have been identified in 50–70% of lung
tumors). With its involvement in cell cycle regulation, DNA
repair and apoptosis, p53 is essential for controlling the in-
tegrity of the genome. At least 3 phase I clinical trials have
been conducted to investigate biosafety and therapeutic effi-
cacy of p53 substitution [35]. Each study was able to demon-
strate the safety of this approach and stabilization of disease
was achieved [36]. However, to date, no gene transfer system
(e.g. viral vectors) is efficient enough to meet the theoretical
need to genetically modify every cancer cell to achieve an op-
timal antitumor effect. In addition, immunity against the viral
vector may compromise the efficiency of this approach. Cur-
rent preclinical studies, therefore, investigate novel gene
transfer vehicles which are less immunogenic.
Another frequent therapeutic target in lung cancer gene re-
placement therapy strategies is the ras oncogene. Ras muta-
tions are found in approximately 20% of adenocarcinomas.
‘Suicide’ Gene Therapy
The in vivo delivery of a ‘suicide’ gene to tumor cells is sup-
posed to result in their selective sensitization to a systemically
administered drug. The most prominent example is the herpes
simplex thymidine kinase (HSV-tk) gene that encodes for an
enzyme that converts the normally nontoxic gancyclovir into a
toxic compound. While there are no reports on clinical appli-
cation of this approach in patients with lung cancer, there is
clinical data utilizing an adenoviral vector to deliver the HSV-
tk gene to patients with mesothelioma via intra-pleural ad-
ministration [37].
‘Immuno’ Gene Therapy
As described above with therapeutic vaccines, immuno gene
therapy aims at enhancing the immunogenicity of lung tumors
and, ultimatively, at inducing a systemic antitumor immune re-
sponse. Most research efforts in NSCLC/SCLC concentrate
on the ex vivo genetic modification of autologous tumor cells,
tumor infiltrating lymphocytes or dendritic cells to secrete im-
munostimulatory cytokines such as IL-2, IL-7 and most of all
GM-CSF [21]. The resulting products have been used for
adoptive cell transfer, therapeutic vaccination, intra-tumoral
application and others. Another promising approach in lung
cancer may be vaccination using gene-modified viral vectors.
Promising early results have been reported for a highly atten-
uated vaccinia virus vector (modified vaccinia Ankara, MVA)
encoded to express the epithelial cancer antigen MUC1 with
coexpression of IL-2 [38].
One of the most promising preclinical developments of im-
munogene therapy targeting the tumor neovascularization in-
volves delivery of a mutant Raf gene to angiogenic blood ves-
sels using integrin-targeted liposomes [39].
Another immuno gene therapy approach is based on the infu-
sion of an oligonucleotide sequence that is complimentary to a
specific mRNA (antisense), selectively downregulating ex-
pression of that protein. Using this strategy, Villalona-Calero
et al. [40] applied the antisense inhibitor of protein kinase C-α
in combination with chemotherapy in patients with advanced
NSCLC and found an overall response rate of 36% in their
phase II study.
Conclusion
The limited information available concerning the antigenic
repertoire of NSCLC and SCLC and the ability to circumvent
the immune response make lung cancer a particularly difficult
target for immunotherapeutic treatment strategies. However,
over the past decades significant advances have been made
and different approaches have been taken from bench to clin-
ic. It remains hopeful that immunotherapy may become part
of today’s established therapies for patients diagnosed with
lung cancer. As a minimally toxic and targeted therapy, thera-
peutic vaccination might be of particular interest to those
treating this terrible disease.
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